Edition:
United Kingdom

EyeGate Pharmaceuticals Inc (EYEG.OQ)

EYEG.OQ on NASDAQ Stock Exchange Capital Market

1.23USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.23
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
28,329
52-wk High
$3.89
52-wk Low
$0.90

Chart for

About

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone... (more)

Overall

Beta: --
Market Cap(Mil.): $20.99
Shares Outstanding(Mil.): 17.20
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Eyegate Pharmaceuticals posts Q3 ‍net loss $4.1 mln vs $3.4 mln a year ago

* Eyegate Pharmaceuticals reports third quarter 2017 financial results and provides business update

14 Nov 2017

BRIEF-EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery

* EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery

08 Nov 2017

BRIEF-Eyegate Pharmaceuticals Q2 revenue $148,000

* Eyegate Pharmaceuticals reports second quarter 2017 financial results and provides business update

07 Aug 2017

BRIEF-Eyegate Pharma enrolls first patient in phase 2b clinical study

* Eyegate Pharma enrolls first patient in phase 2b clinical study of EGP-437 for cataract surgery Source text for Eikon: Further company coverage:

01 Aug 2017

BRIEF-Armistice Capital LLC reports 9.9 percent passive stake in Eyegate Pharmaceuticals Inc

* Armistice Capital LLC reports 9.9 percent passive stake in Eyegate Pharmaceuticals Inc, as of June 9, 2017 Source text: (http://bit.ly/2sM4eCk) Further company coverage:

19 Jun 2017

BRIEF-Innoven Partenaires reports a 9.5 pct stake in Eyegate Pharmaceuticals

* Innoven Partenaires S.A. reports a 9.5 percent stake in Eyegate Pharmaceuticals Inc as of June 14 - SEC filing

16 Jun 2017

BRIEF-Empery Asset Management reports 9.22 pct passive stake in Eyegate Pharmaceuticals

* Empery Asset Management LP reports a 9.22 percent passive stake in Eyegate Pharmaceuticals Inc as of June 9, 2017 - SEC filing Source text: (http://bit.ly/2saWqql) Further company coverage:

14 Jun 2017

Earnings vs. Estimates